Factors influencing daily treatment choices in multiple
sclerosis: practice guidelines, biomarkers and burden of
disease

J 2020

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN et. al.

Basic information

Original name

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

Authors

BERGER, Thomas (40 Austria, guarantor), Monika ADAMCZYK-SOWA (616 Poland), Tunde CSEPANY (348 Hungary), Franz FAZEKAS (620 Portugal), Tanja Hojs FABJAN (705 Slovenia), Dana HORAKOVA (203 Czech Republic), Alenka Horvat LEDINEK (705 Slovenia), Zsolt ILLES (208 Denmark), Gisela KOBELT (752 Sweden), Sasa Sega JAZBEC (705 Slovenia), Eleonora KLIMOVA (703 Slovakia), Fritz LEUTMEZER (620 Portugal), Konrad REJDAK (616 Poland), Csilla ROZSA (348 Hungary), Johann SELLNER (40 Austria), Krzysztof SELMAJ (616 Poland), Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution), Jarmila SZILASIOVA (703 Slovakia), Peter TURCANI (703 Slovakia), Marta VACHOVA (203 Czech Republic), Manuela VANECKOVA (203 Czech Republic), Laszlo VECSEI (348 Hungary) and Eva Kubala HAVRDOVA (203 Czech Republic)

Edition

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, LONDON, SAGE PUBLICATIONS LTD, 2020, 1756-2856

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.570

RIV identification code

RIV/00216224:14110/20:00117694

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1177/1756286420975223

UT WoS

000597939700001

Keywords in English

biomarkers; burden of disease; cognitive dysfunction; magnetic resonance imaging; multiple sclerosis; neurofilament

Abstract

V originále

At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.

Citovat

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN, Dana HORAKOVA, Alenka Horvat LEDINEK, Zsolt ILLES, Gisela KOBELT, Sasa Sega JAZBEC, Eleonora KLIMOVA, Fritz LEUTMEZER, Konrad REJDAK, Csilla ROZSA, Johann SELLNER, Krzysztof SELMAJ, Pavel ŠTOURAČ, Jarmila SZILASIOVA, Peter TURCANI, Marta VACHOVA, Manuela VANECKOVA, Laszlo VECSEI and Eva Kubala HAVRDOVA. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. LONDON: SAGE PUBLICATIONS LTD, 2020, vol. 13, DEC 2020, p. 1-13. ISSN 1756-2856. Available from: https://dx.doi.org/10.1177/1756286420975223.

@article{1725937,
   author = {Berger, Thomas and AdamczykandSowa, Monika and Csepany, Tunde and Fazekas, Franz and Fabjan, Tanja Hojs and Horakova, Dana and Ledinek, Alenka Horvat and Illes, Zsolt and Kobelt, Gisela and Jazbec, Sasa Sega and Klimova, Eleonora and Leutmezer, Fritz and Rejdak, Konrad and Rozsa, Csilla and Sellner, Johann and Selmaj, Krzysztof and Štourač, Pavel and Szilasiova, Jarmila and Turcani, Peter and Vachova, Marta and Vaneckova, Manuela and Vecsei, Laszlo and Havrdova, Eva Kubala},
   article_location = {LONDON},
   article_number = {DEC 2020},
   doi = {http://dx.doi.org/10.1177/1756286420975223},
   keywords = {biomarkers; burden of disease; cognitive dysfunction; magnetic resonance imaging; multiple sclerosis; neurofilament},
   language = {eng},
   issn = {1756-2856},
   journal = {THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS},
   title = {Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease},
   url = {https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223},
   volume = {13},
   year = {2020}
}

TY  - JOUR
ID  - 1725937
AU  - Berger, Thomas - Adamczyk-Sowa, Monika - Csepany, Tunde - Fazekas, Franz - Fabjan, Tanja Hojs - Horakova, Dana - Ledinek, Alenka Horvat - Illes, Zsolt - Kobelt, Gisela - Jazbec, Sasa Sega - Klimova, Eleonora - Leutmezer, Fritz - Rejdak, Konrad - Rozsa, Csilla - Sellner, Johann - Selmaj, Krzysztof - Štourač, Pavel - Szilasiova, Jarmila - Turcani, Peter - Vachova, Marta - Vaneckova, Manuela - Vecsei, Laszlo - Havrdova, Eva Kubala
PY  - 2020
TI  - Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease
JF  - THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
VL  - 13
IS  - DEC 2020
SP  - 1-13
EP  - 1-13
PB  - SAGE PUBLICATIONS LTD
SN  - 17562856
KW  - biomarkers
KW  - burden of disease
KW  - cognitive dysfunction
KW  - magnetic resonance imaging
KW  - multiple sclerosis
KW  - neurofilament
UR  - https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223
L2  - https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223
N2  - At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.
ER  -

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN, Dana HORAKOVA, Alenka Horvat LEDINEK, Zsolt ILLES, Gisela KOBELT, Sasa Sega JAZBEC, Eleonora KLIMOVA, Fritz LEUTMEZER, Konrad REJDAK, Csilla ROZSA, Johann SELLNER, Krzysztof SELMAJ, Pavel ŠTOURAČ, Jarmila SZILASIOVA, Peter TURCANI, Marta VACHOVA, Manuela VANECKOVA, Laszlo VECSEI and Eva Kubala HAVRDOVA. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. \textit{THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS}. LONDON: SAGE PUBLICATIONS LTD, 2020, vol.~13, DEC 2020, p.~1-13. ISSN~1756-2856. Available from: https://dx.doi.org/10.1177/1756286420975223.

Detailed Information on Publication Record